Autonomix Medical, Inc. Granted Approval to Expand Proof-of-Concept Human Clinical Study, Doubling Potential Addressable Market Beyond Pancreatic Cancer Pain
Ethics committee authorization supports platform expansion into visceral cancer pain for proprietary ablation technology
Expansion supports Autonomix's strategy to build long-term value through multi-indication growth
Patient enrollment expected to begin in June 2025
THE WOODLANDS, TX, June 05, 2025 (GLOBE NEWSWIRE) — Autonomix Medical, Inc. (NASDAQ: AMIX) ('Autonomix' or the 'Company'), a medical device company focused on advancing innovative technologies to revolutionize how diseases involving the nervous system are diagnosed and treated, today announced that it has received Ethics Committee authorization from the Ministry of Health of the Republic of Uzbekistan to open the clinical trial site for the follow-on phase to its proof-of-concept human clinical trial ('PoC 2') evaluating the safety and effectiveness of delivering transvascular energy to ablate relevant problematic nerves and mitigate cancer pain. The Company is on track to commence enrollment in June 2025.
'This next phase of our clinical program represents a meaningful advancement for Autonomix,' said Brad Hauser, CEO of Autonomix. 'With Ethics Committee approval, we can now expand our evaluation beyond severe pancreatic cancer pain to include a broader range of visceral cancers. The initial phase of our study in late-stage pancreatic cancer patients delivered promising results, demonstrating significant pain reduction, substantial decreases in opioid use, and meaningful improvements in quality of life. These outcomes reinforce our belief that Autonomix's technology has the potential to address multiple cancer indications with significant unmet need and transform the standard of care. As we build on this momentum, we see a clear opportunity to create long-term value by unlocking a broader set of impactful clinical applications.'
As previously announced, based on the positive results demonstrated in the initial phase of the Company's first-in-human proof-of-concept trial ('PoC 1') in patients with severe pancreatic cancer pain, Autonomix is initiating a follow-on PoC 2 phase in a market expansion opportunity, which has the potential to double the addressable market beyond pancreatic cancer pain by evaluating additional visceral cancers that signal pain through the Celiac Plexus and earlier stage pancreatic cancers with moderate to severe pain.
Autonomix's technology constitutes a platform with the potential to address dozens of indications, including cardiology, hypertension and chronic pain management, across a wide disease spectrum. The PoC 2 phase will provide a concentrated focus on interventional cancer pain management applications like pancreatic, gall bladder, liver, and bile duct, with potential further expansion in oncology, gastroenterology, and other sectors where the Company has established key opinion leader relationships and emerging preclinical evidence.
For more information about the Company's technology, please visit autonomix.com.
About Autonomix Medical, Inc.
Autonomix is a medical device company focused on advancing innovative technologies to revolutionize how diseases involving the nervous system are diagnosed and treated. The Company's first-in-class platform system technology includes a catheter-based microchip sensing array that may have the ability to detect and differentiate neural signals with greater sensitivity than currently available technologies. We believe this will enable, for the first time ever, transvascular diagnosis and treatment of diseases involving the peripheral nervous system virtually anywhere in the body.
We are initially developing this technology for the treatment of pain, with initial trials focused on pancreatic cancer, a condition that causes debilitating pain and is without a reliable solution. Our technology constitutes a platform to address dozens of potential indications, including cardiology, hypertension and chronic pain management, across a wide disease spectrum. Our technology is investigational and has not yet been cleared for marketing in the United States.
For more information, visit autonomix.com and connect with the Company on X, LinkedIn, Instagram and Facebook.
Forward Looking Statements
Some of the statements in this release are 'forward-looking statements,' which involve risks and uncertainties. Forward-looking statements in this press release include, without limitation, the timing of the commencement of the PoC 2 phase of the trial. Such forward-looking statements can be identified by the use of words such as 'should,' 'might,' 'may,' 'intends,' 'anticipates,' 'believes,' 'estimates,' 'projects,' 'forecasts,' 'expects,' 'plans,' and 'proposes.'
Although Autonomix believes that the expectations reflected in these forward-looking statements are based on reasonable assumptions, there are a number of risks and uncertainties that could cause actual results to differ materially from such forward-looking statements. You are urged to carefully review and consider any cautionary statements and other disclosures, including the statements made under the heading 'Risk Factors' and elsewhere in the Annual Report on Form 10-K filed with the U.S. Securities and Exchange Commission ('SEC') on May 31, 2024 and in other filings made by us from time to time with the SEC. Forward-looking statements speak only as of the date of the document in which they are contained and Autonomix does not undertake any duty to update any forward-looking statements except as may be required by law.
Investor and Media ContactJTC Team, LLCJenene Thomas908.824.0775
[email protected]
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
an hour ago
- Yahoo
Microsoft Surges Past $4T Market Cap After Blowout Earnings
Shares of Microsoft Corp. (MSFT) jumped nearly 5% Thursday following a stellar earnings report, pushing its market capitalization past $4 trillion for the first time. Microsoft becomes only the second company to reach that milestone, following Nvidia Corp. (NVDA), which crossed the threshold three weeks earlier. The software giant's gains helped propel major ETFs to new heights. The Vanguard S&P 500 ETF (VOO), which holds a 7% allocation to Microsoft, and the Invesco QQQ Trust (QQQ), where Microsoft represents 9% of the portfolio, both traded at all-time highs. MSFT Earnings Strength In its fiscal fourth quarter, Microsoft reported earnings per share of $3.65, beating Wall Street estimates of $3.37. Revenue came in at $76.4 billion, topping expectations by 3.5% and marking an 18% increase from the prior year. At the heart of the company's growth story is artificial intelligence. Microsoft continues to embed AI into its own software products while offering cloud-based AI infrastructure to other companies through Azure, which has emerged as a key driver of growth. According to CEO Satya Nadella, Azure alone generated more than $75 billion in revenue over the past year, rising 34% from the year before. 'Cloud and AI is the driving force of business transformation across every industry and sector,' Nadella said. 'We're innovating across the tech stack to help customers adapt and grow in this new era.' The broader "Azure and other cloud services" category grew by 39%, its fastest pace since 2022. Demand has been so strong that Microsoft has struggled to keep up. Despite ramping up capacity, Nadella acknowledged that supply remains constrained. Even OpenAI—Microsoft's high-profile AI partner, in which it holds a significant stake—has had to lean on other cloud providers like Oracle to meet its compute needs due to bottlenecks in Microsoft's infrastructure. Investors Bet on AI Demand To close the gap, Microsoft plans to spend a staggering $30 billion on capital expenditures this quarter alone. So far, investors appear supportive of the aggressive investment strategy, betting that AI demand will justify the outlay. The developments also bode well for Nvidia, whose chips power much of the AI infrastructure underpinning Microsoft's growth. As the AI race intensifies, ETF investors continue to benefit, especially those in funds with heavy exposure to the megacaps leading the | © Copyright 2025 All rights reserved
Business Wire
an hour ago
- Business Wire
DYNX Stock Alert: Halper Sadeh LLC Is Investigating Whether the Merger of Dynamix Corporation Is Fair to Shareholders
NEW YORK--(BUSINESS WIRE)--Halper Sadeh LLC, an investor rights law firm, is investigating whether the merger of Dynamix Corporation (NASDAQ: DYNX) and The Ether Machine, Inc. is fair to Dynamix shareholders. Halper Sadeh encourages Dynamix shareholders to click here to learn more about their legal rights and options or contact Daniel Sadeh or Zachary Halper at (212) 763-0060 or sadeh@ or zhalper@ The investigation concerns whether Dynamix and its board violated the federal securities laws and/or breached their fiduciary duties to shareholders by failing to, among other things: (1) obtain the best possible consideration for Dynamix shareholders; and (2) disclose all material information necessary for Dynamix shareholders to adequately assess and value the merger consideration. On behalf of Dynamix shareholders, Halper Sadeh LLC may seek increased consideration for shareholders, additional disclosures and information concerning the proposed transaction, or other relief and benefits. We would handle the action on a contingent fee basis, whereby you would not be responsible for out-of-pocket payment of our legal fees or expenses. Halper Sadeh LLC represents investors all over the world who have fallen victim to securities fraud and corporate misconduct. Our attorneys have been instrumental in implementing corporate reforms and recovering millions of dollars on behalf of defrauded investors. Attorney Advertising. Prior results do not guarantee a similar outcome.
CNBC
an hour ago
- CNBC
Figma's top VCs are sitting on $24 billion worth of stock after massive IPO pop
You can almost smell the bubbly wafting across Silicon Valley. Following Figma's blockbuster market debut on Thursday, four of the most iconic names in venture capital — Index Ventures, Greylock, Kleiner Perkins and Sequoia — are collectively sitting on roughly $24 billion worth of the design software vendor's stock. Until recently, there's been little reason to celebrate. From late 2021, when soaring inflation and rising rates pushed investors out of risky assets, until the middle of 2025, tech IPOs were few and far between, and many of the companies that managed to make it out failed to impress Wall Street. That's left venture firms with scarce returns for the pension funds, endowments and foundations they rely on for funding. The mood is noticeably brighter these days as the Nasdaq trades near a record. Figma is the latest, and perhaps most high-profile, tech company to hit the market, and Wall Street appears to want more. After raising its price range this week and then pricing $1 above the top of that range, Figma shares soared 250% in their first day on the New York Stock Exchange. Investors will admit they got lucky. Figma was supposed to get acquired for $20 billion by Adobe, an agreement the two companies forged in 2022. But the following year, the transaction collapsed after U.K. regulators said the tie-up would harm competition. Figma is now worth more than three times what Adobe was going to pay, closing on Thursday with a market cap of almost $68 billion. CEO Dylan Field, who co-founded the company in 2012, owns a stake worth over $6 billion. Danny Rimer, a partner at Index Ventures and Figma board member, wrote in a blog post on Thursday that the failed acquisition came with "intense pressure and a spotlight few founders ever face." "Dylan remained his usual grounded, transparent self," wrote Rimer, whose firm first bet on Figma in 2013 and is the biggest shareholder, with $7.2 billion worth of stock in the company. "When the deal fell through a year later, he didn't flinch. He turned the page and got right back to building." Figma's offering raised $1.2 billion, with two-thirds of the proceeds going to existing investors. Other than the small slug of stock each of the venture firms sold at $33, the rest of their holdings are subject to a lock-up period, meaning all of the current value is currently just on paper. The vast majority of outstanding shares are locked up for 180 days, so big stock sales can't happen until January. Stablecoin issuer Circle went public in June, and is the other tech IPO that's generated hefty returns for VCs recently. The shares were initially sold at $31 each and are now trading at over $183, leaving investment firms IDG Capital, General Catalyst, Accel and Breyer Capital with a combined stake of close to $12 billion. Circle doubled on its first day of trading. While IPO pops generate a lot of buzz and dramatically lift the value of investors' holdings, they're not universally celebrated. Bill Gurley of Benchmark has for years been a critic of such first-day gains, arguing that bankers leave money on the table for the company while handing deeply discounted stock to new investors. In a series of posts on X on Thursday, Gurley described the Figma outcome as "expected & fully intentional." "Who benefits?" Gurley wrote, shortly after the stock began trading. "The large clients of the investment banks (who return the favor paying for other services). They bought it at $33 last night and can sell it today for over $90." Still, the exuberance in the market is welcome news for most VCs. After a record year in 2021, which saw 155 U.S. venture-backed IPOs raise $60.4 billion, every year since has been relatively dismal, according to data from University of Florida finance professor Jay Ritter. There were 13 such offerings in 2022, followed by 18 in 2023 and 30 last year, collectively raising $13.3 billion, Ritter's data shows. The slowdown followed the Federal Reserve's aggressive rate-hiking campaign in 2022, meant to slow crippling inflation. As the lower-growth environment extended into years two and three, venture firms faced increasing pressure to return cash to investors. Earlier this year, the exit environment was still looking ominous. After President Donald Trump's announcement of sweeping tariffs in April, companies including online lender Klarna and ticket marketplace StubHub delayed their IPO plans. The Nasdaq plummeted 10% in a week, as investors fretted over the potential of rising import costs and supply chain disruptions. But Trump later walked back his threats and the trade deals he's landed have resulted in lower tariffs than previously feared. CoreWeave, a provider of artificial intelligence infrastructure, went public just before Trump's initial plans were announced. The stock is now almost triple its IPO price, closing on Thursday at $114.13, though that's down about 38% from its high in June. CoreWeave and Circle have both been big wins for investors, with their market caps now at about $56 billion and $41 billion, respectively. Figma is worth even more. Lynn Martin, president of the NYSE, told CNBC's "Squawk on the Street" on Thursday that she thinks the Figma offering "will open the floodgates." Figma's early investors and big financial winners all published glowing blog posts about Field and the journey he's been on with the company that he started after dropping out of college in 2012. "Figma's relentless focus on product, community, and craft has reshaped how the world designs," wrote Greylock's John Lilly in a post on Thursday. His firm led the $14 Series AI investment in 2015 and now owns a stake worth about $6.7 billion. Kleiner Perkins led the $25 Series B, which was announced in 2018. Its holdings are now valued at $6 billion. "The product was still early, but the love from its small community of users was unmistakable," wrote Kleiner partner Mamoon Hamid, in his post after the IPO. "We were convinced that Figma had the potential to fundamentally reshape how digital products would be designed, and knew we had to be part of it." Two years later, venture powerhouse Sequoia stepped in to lead Figma's $40 million Series C round. Sequoia's Andrew Reed wrote at the time that the company had "the talent and culture to build an enduring, fundamental company." On Thursday, with his firm's stake in Figma approaching $3.8 billion, Reed took to X for his congratulatory remarks. "Congrats to the incredible @Figma team," Reed wrote. "The most creative, determined, imaginative, and positive group of people. I'm just so happy for all of your success."
